Scientific Search: 5 Key Concepts You Need to Know
How can researchers cope with the deluge of data at their disposal and search more efficiently? Here’s a look at several key scientific search concepts.
Amazon Continues with Bold Pharma Plays, Acquiring Startup Pharmacy PillPack
Amazon recently acquired PillPack – a startup pharmacy that currently serves a small segment of patients who are on a number of different medications.
The Evolving Role of Medical Affairs – And 2 Ways to Keep Up
Medical affairs is a hub of data and information generation, sharing and dissemination. Here are three ways they can help deliver strategic value.
How the FDA Plans to Modernize New Drugs Review Process
The FDA wants to empower the agency’s scientists and medical officers to take on more “thought leadership.” Here’s how they plan to do it.
3 Takeaways for Pharma Orgs from President Trump’s ‘American Patients First’ Speech
Analysts can’t decide whether the “American Patients First” program will serve U.S. consumers well in the long run, but most agreed that the administration is right in attempting to tackle the complex and important issue of drug prices.
Technology a Stumbling Block for Pharma Firms in their Digital Transformation Journey
New research, conducted in Q4 2017 by TayganPoint Consulting Group and PharmaVoice, reveals that more than one in four life sciences companies expect large-scale transformation in the next three years.
62% of Drug Safety Experts Say They’re Using AI to Improve Adverse Event Reporting
Is it time for pharmacovigilance teams to utilize AI applications to improve adverse event reporting?
5 Considerations for a New Pharmacovigilance Literature Review Workflow
As you consider more efficient approaches for monitoring, searching, and distributing results to the pharmacovigilance team, here’s one information manager’s advice.
FDA’s Proposed New Knowledge Management System to Make Drug Development More Efficient
The FDA’s 2019 budget request is $5.8 billion. Here’s a look at what Commissioner Scott Gottlieb plans to do with the funds.
Should Commercial Teams be Involved Earlier in the Drug Development Cycle? Research Suggests Yes
Commercial teams can no longer afford to be operating separately from R&D – silos between the two operations will start to break down.